leadf
logo-loader
viewMedlab Clinical Ltd

Medlab Clinical's NanoCBD available in Australia with first SAS scheme patient supplied

The company’s newest cannabinoid formulation treats patients with chemotherapy-induced nausea and vomiting (CINV).

Medlab Clinical Ltd - Medlab Clinical NanoCBD product available in Australia
NanoCBD will undergo clinical trials for the treatment of CINV for drug approvals

Medlab Clinical Ltd's (ASX:MDC) newest cannabinoid formulation, NanoCBD, is now available in Australia, with the first patient supplied under the Australian Government’s Special Access Scheme (SAS)

The drug is intended for the treatment of patients with chemotherapy-induced nausea and vomiting (CINV), and like NanaBis™, shares the same proprietary delivery platform, NanoCelle™.

MDC's chief executive officer Dr Sean Hall said: “NanoCBD is a fantastic product to be supplied alongside our lead drug candidate NanaBis™.

“Unlike NanaBis, NanoCBD is a CBD only product, but like NanaBis™ it is a further example of the optionality of our NanoCelle™ delivery system.”

Beyond Australia and Hong Kong, where the first shipment of NanoCBD has also recently been received, Medlab is now focusing discussions on trade expansion in the Northern Hemisphere markets.

CBD only formulation

NanoCBD is a CBD only formulation, manufactured in a US, Food and Drug Administration (FDA) approved facility, with analytical work conducted at a US FDA approved testing laboratory.

Unlike other CBD oils, tablets, or capsules the drug:

  • Is a submicron spray validated to be 21.29 nanometres delivering 5 milligrams/0.3 millilitres,  
  • Is not subject to known product degradation (1st pass metabolism) as it is administered to the oro-buccal membrane and not ingested, and
  • Mechanistically utilises the facial lymphatics for systemic delivery, allowing a more rapid response.

Clinical trials planned

In parallel to being made available under the SAS, NanoCBD will undergo clinical trials for the treatment of CINV for drug approvals.

Dr Hall said: “NanoCBD is manufactured to a drug standard, and because it shares a number of similarities to NanaBis™, we believe NanoCBD is well placed to offer a more scientific and medically plausible offering in global markets.”

Quick facts: Medlab Clinical Ltd

Price: 0.2 AUD

ASX:MDC
Market: ASX
Market Cap: $55.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read